vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate

vTv Therapeutics, Inc. Class A

vTv Therapeutics, Inc. Class A

VTVT

0.00

vTv Therapeutics (NASDAQ: VTVT) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 14.13 percent decrease over losses of $(0.92) per share from the same period last year.